Worth Watching Stocks: MGM Resorts International (NYSE:MGM), Bristol-Myers Squibb Company (NYSE:BMY), Emmis Communications Corp. (NASDAQ:EMMS), O’Reilly Automotive Inc. (NASDAQ:ORLY), TransAlta Corp. (NYSE:TAC)

MGM Resorts International (NYSE:MGM) EVP Phyllis James sold 4,875 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $25.00, for a total transaction of $121,875.00. MGM Resorts International (NYSE:MGM) belongs to Services sector. Its net profit margin is 1.40% and weekly performance is -1.03%. On last trading day company shares ended up $24.89. … Continue reading Worth Watching Stocks: MGM Resorts International (NYSE:MGM), Bristol-Myers Squibb Company (NYSE:BMY), Emmis Communications Corp. (NASDAQ:EMMS), O’Reilly Automotive Inc. (NASDAQ:ORLY), TransAlta Corp. (NYSE:TAC)

Healthcare ACtive Stocks: MannKind (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Bristol-Myers Squibb Co (NYSE:BMY)

MannKind Corporation (NASDAQ: MNKD) is a small company based in Valencia, California, poised to launch its FDA approved drug, Afrezza, as treatment indications for both Type 1 and Type 2 diabetes. Despite near unanimous backing from experts at the Advisory Committee (ADCOM) and the medical community, Mr. Market is still pessimistic on the company. MannKind Corporation (NASDAQ:MNKD) stock performance was -2.50% in last session and finished the … Continue reading Healthcare ACtive Stocks: MannKind (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Bristol-Myers Squibb Co (NYSE:BMY)

Arena Pharmaceuticals, Inc.’s (NASDAQ:ARNA ) shares dropped 9.4% following news that its CEO Jack Lief, has sold around 40% of his stake in the company. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock performance was -5.29% in last session and finished the day at $5.01. Traded volume was 7.44million shares in the last session and the average volume of the stock remained 4.98million shares. The beta of the … Continue reading Healthcare Active Stocks: Arena Pharmaceuticals (NASDAQ:ARNA), Bristol-Myers Squibb (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), TherapeuticsMD (NYSEMKT:TXMD), Boston Scientific (NYSE:BSX)

According to a statement of Orexigen Therapeutics, Inc. (NASDAQ:OREX), the U.S Food and Drug Administration hasn’t given a green signal to its new drug which helps people in fighting from obesity. One of the spokespersons of the company said,” FDA has delayed its decision on our drug for as much as 3 months. So we will be able to get a final call only after … Continue reading Healthcare most active stocks: Orexigen Therapeutics (NASDAQ:OREX), Express Scripts Holding (NASDAQ:ESRX), Karyopharm Therapeutics Inc (NASDAQ:KPTI), Novavax (NASDAQ:NVAX), Bristol-Myers Squibb (NYSE:BMY)

Zogenix, Inc (NASDAQ:ZGNX) CEO Roger Hawley unloaded 25,078 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $2.10, for a total transaction of $52,663.80. Following the completion of the sale, the chief executive officer now directly owns 1,204,447 shares in the company, valued at approximately $2,529,339. Zogenix, … Continue reading Healthcare Active Movers: Zogenix, Inc. (NASDAQ:ZGNX), Orexigen Therapeutics (NASDAQ:OREX), Merck & Co (NYSE:MRK), Boston Scientific Corporation (NYSE:BSX), Bristol-Myers Squibb (NYSE:BMY)

Johnson & Johnson (NYSE: JNJ) has inked a global licensing deal with the privately held Aduro BioTech for developing new therapies to treat prostate cancer. According to the oncology deal, the private company granted Janssen Biotech, a division of Johnson & Johnson, the exclusive license to certain candidates specifically engineered for the treatment of prostate cancer on the basis of Aduro’s proprietary live-attenuated double-deleted (LADD) … Continue reading Healthcare Active Stocks: Johnson & Johnson (NYSE:JNJ), Endo International (NASDAQ:ENDP), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb (NYSE:BMY)